Key Segmentation:
By Method
-
Viral Removal
-
Viral Inactivation
-
Hybrid Strategies
By Application
-
Recombinant Proteins
-
Monoclonal Antibodies
-
Tissue & Blood-derived Products
-
Vaccines
-
Gene & Cell Therapies
-
Viral Vectors
-
Other Applications
By End User
-
Large Pharma
-
Small & Mid-size Biotech
-
Contract Development & Manufacturing Organizations
-
Contract Research & Testing Organizations
-
Academic & Government Research Institutes
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market player
Frequently Asked Questions
Leading companies include Charles River Laboratories, Lonza Group, Merck KGaA, Texcell, WuXi AppTec, WuXi Biologics, Sartorius, Eurofins Scientific, Catalent, and Fujifilm Diosynth Biotechnologies, among others.
Key opportunities include platform validation, risk-based AAV studies, sequencing-enabled virus detection, and expanding viral clearance capacity across Asia Pacific.
Growth is primarily driven by surging demand for viral safety validation across biologics, vaccines, and advanced modalities such as cell and gene therapies, combined with rising outsourcing to specialist CDMOs and CROs.
By Method, Viral Removal dominates the market with approximately 60.12% share in 2025, reflecting its status as the backbone of bioprocess safety validation.
North America dominates the market with approximately 38.85% share in 2025, supported by regulatory leadership, venture funding, and large-scale biomanufacturing plant expansions.
